Perfusion-diffusion 1H spectroscopy: Role in the diagnosis and follow-up of supratentorial brain tumours in adults;Spectroscopie 1H, perfusion, diffusion: Quelle place pour ces techniques lors du diagnostic et du suivi des principales tumeurs cérébrales sus-tentorielles de l'adulte?

Revue Neurologique

Volumn 162, Issue 12, 2006, Pages 1204-1220

  Grand, S ^a   Kremer, S ^b   Tropres, I ^a   Pasteris, C ^a   Krainik, A ^a   Hoffmann, D ^a   Chabardes, S ^a   Berger, F ^a   Pasquier, B ^a   Lefournier, V ^a   Le Bas, J F ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Brain tumors; Diffusion; Perfusion; Spectroscopy

Indexed keywords

CORTICOSTEROID; GADOLINIUM;

ANGIOGENESIS; BRAIN TUMOR; CANCER GRADING; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; DIAGNOSTIC IMAGING; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; IMAGING SYSTEM; LYMPHOCYTOMA; LYMPHOMA; MENINGIOMA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERFUSION WEIGHTED IMAGING; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; TUMOR DIAGNOSIS; ADULT; ASTROCYTOMA; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PATHOLOGY;

ADULT; ASTROCYTOMA; GLIOBLASTOMA; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; SUPRATENTORIAL NEOPLASMS;

EID: 33845736430     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(06)75134-7     Document Type: Review

References (54)

1. AUER DP, GOSSL C, SCHIRMER T, CZISCH M. (2001). Improved analysis of 1H-MR spectra in the presence of mobile lipids. Magn Reson Med, 46: 615-618.
2. CASTILLO M, SMITH JK, KWOCK L. (2000). Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol, 21: 1645-1649.
3. CHA S, TIHAN T, CRAWFORD F et al. (2005). Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol, 26: 266-273.
4. CHIANG IC, KUO YT, LU CY et al. (2004). Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology, 46: 619-627.
5. COONS SW, JOHNSON PC, SCHEITHAUER BW, YATES AJ, PEARL DK. (1997). Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer, 79: 1381-1393.
6. COUSINS JP. (1995). Clinical MR spectroscopy: fundamentals, current applications, and future potential. AJR Am J Roentgenol, 164: 1337-1347.
7. DE EDELENYI FS, RUBIN C, ESTEVE F et al. (2000). A new approach for analyzing proton magnetic resonance spectroscopic images of brain tumors: nosologic images. Nat Med, 6: 1287-1289.
8. DOUSSET V, DELALANDE C, BALLARINO L et al. (1999). In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance. Magn Reson Med, 41: 329-333.
9. DUCREUX D, WU RH, MIKULIS DJ, TERBRUGGE K. (2003). Diffusion-weighted imaging and single-voxel MR spectroscopy in a case of malignant cerebral lymphoma. Neuroradiology, 45: 865-868.
10. EBISU T, TANAKA C, UMEDA M et al. (1996). Discrimination of brain abscess from necrotic or cystic tumors by diffusion-weighted echo planar imaging. Magn Reson Imaging, 14: 1113-1116.
11. ESTEVE F, RUBIN C, GRAND S, KOLODIE H, LE BAS JF. (1998). Transient metabolic changes observed with proton MR spectroscopy in normal human brain after radiation therapy. Int J Radiat Oncol Biol Phys, 40: 279-286.
12. FORSTING M, ALBERT FK, KUNZE S, ADAMS HP, ZENNER D, SARTOR K. (1993). Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns. AJNR Am J Neuroradiol, 14: 77-87.
13. GALANAUD D, CHINOT O, NICOLI F et al. (2003). Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg, 98: 269-276.
14. GANSLANDT O, STADLBAUER A, FAHLBUSCH R et al. (2005). Proton Magnetic Resonance Spectroscopic Imaging Integrated into Image-guided Surgery: Correlation to Standard Magnetic Resonance Imaging and Tumor Cell Density. Neurosurgery, 56: 291-298.
15. GRAND S, PASSARO G, ZIEGLER A et al. (1999). Necrotic tumor versus brain abscess: importance of amino acids detected at 1H MR spectroscopy - initial results. Radiology, 213: 785-793.
16. GRAVES EE, NELSON SJ, VIGNERON DB et al. (2001). Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol, 22: 613-624.
17. HARTING I, HARTMANN M, JOST G et al. (2003). Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy. Neurosci Lett, 342: 163-166.
18. HARTMANN M, HEILAND S, HARTING I et al. (2003). Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett, 338: 119-122.
19. HEESTERS MA, KAMMAN RL, MOOYAART EL, GO KG. (1993). Localized proton spectroscopy of inoperable brain gliomas. Response to radiation therapy. J Neurooncol, 17: 27-35.
20. HERMINGHAUS S, DIERKS T, PILATUS U et al. (2003). Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data. J Neurosurg, 98: 74-81.
21. HERMINGHAUS S, PILATUS U, MOLLER-HARTMANN W et al. (2002). Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed, 15: 385-392.
22. HOLMES TM, PETRELLA JR, PROVENZALE JM. (2004). Distinction between cerebral abscesses and high-grade neoplasms by dynamic susceptibility contrast perfusion MRI. AJR Am J Roentgenol, 183: 1247-1252.
23. HOWE FA, OPSTAD KS. (2003). 1H MR spectroscopy of brain tumours and masses. NMR Biomed, 16: 123-131.
24. HUNT MA, BAGO AG, NEUWELT EA. (2005). Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors by using ferumoxtran-10. AJNR Am J Neuroradiol, 26: 1084-1088.
25. KIRCHER MF, MAHMOOD U, KING RS, WEISSLEDER R, JOSEPHSON L. (2003). A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res, 63: 8122-8125.
26. KRABBE K, GIDEON P, WAGN P, HANSEN U, THOMSEN C, MADSEN F. (1997). MR diffusion imaging of human intracranial tumours. Neuroradiology, 39: 483-489.
27. KREMER S, GRAND S, BERGER F et al. (2003). Dynamic contrast-enhanced MRI: differentiating melanoma and renal carcinoma metastases from high-grade astrocytomas and other metastases. Neuroradiology, 45: 44-49.
28. KREMER S, GRAND S, REMY C et al. (2004). Contribution of dynamic contrast MR imaging to the differentiation between dural metastasis and meningioma. Neuroradiology, 46: 642-648.
29. LAI PH, HO JT, CHEN WL et al. (2002). Brain abscess and necrotic brain tumor: discrimination with proton MR spectroscopy and diffusion-weighted imaging. AJNR Am J Neuroradiol, 23: 1369-1377.
30. LAUNDRE BJ, JELLISON BJ, BADIE B, ALEXANDER AL, FIELD AS. (2005). Diffusion tensor imaging of the corticospinal tract before and after mass resection as correlated with clinical motor findings: preliminary data. AJNR Am J Neuroradiol, 26: 791-796.
31. LAW M, CHA S, KNOPP EA, JOHNSON G, ARNETT J, LITT AW. (2002). High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology, 222: 715-721.
32. LEE YY, VAN TASSEL P, BRUNER JM, MOSER RP, SHARE JC. (1989). Juvenile pilocytic astrocytomas: CT and MR characteristics. AJR Am J Roentgenol, 152: 1263-1270.
33. LEV MH, OZSUNAR Y, HENSON JW et al. (2004). Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol, 25: 214-221.
34. LICHY MP, PLATHOW C, SCHULZ-ERTNER D, KAUCZOR HU, SCHLEMMER HP. (2005). Follow-up gliomas after radiotherapy: 1H MR spectroscopic imaging for increasing diagnostic accuracy. Neuroradiology, 47: 826-834.
35. MAEDA M, ITOH S, KIMURA H et al. (1993). Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology, 189: 233-238.
36. MAIA AC, MALHEIROS SM, DA ROCHA AJ et al. (2004). Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion-weighted magnetic resonance imaging. J Neurosurg, 101: 970-976.
37. MAIURI F, IACONETTA G, DE DIVITIIS O, CIRILLO S, DI SALLE F, DE CARO ML. (1999). Intracranial meningiomas: correlations between MR imaging and histology. Eur J Radiol, 31: 69-75.
38. MCKNIGHT TR. (2004). Proton magnetic resonance spectroscopic evaluation of brain tumor metabolism. Semin Oncol, 31: 605-617.
39. NEGENDANK WG, SAUTER R, BROWN TR et al. (1996). Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg, 84: 449-458.
40. NELSON SJ, VIGNERON DB, DILLON WP. (1999). Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. NMR Biomed, 12: 123-138.
41. NEUWELT EA, VARALLYAY P, BAGO AG, MULDOON LL, NESBIT G, NIXON R. (2004). Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours. Neuropathol Appl Neurobiol, 30: 456-471.
42. OTT D, HENNIG J, ERNST T. (1993). Human brain tumors: assessment with in vivo proton MR spectroscopy. Radiology, 186: 745-752.
43. PETRELLA JR, PROVENZALE JM. (2000). MR perfusion imaging of the brain: techniques and applications. AJR Am J Roentgenol, 175: 207-219.
44. REIJNEVELD JC, VAN DER GROND J, RAMOS LM, BROMBERG JE, TAPHOORN MJ. (2005). Proton MRS imaging in the follow-up of patients with suspected low-grade gliomas. Neuroradiology, 47: 887-891.
45. RIJPKEMA M, SCHUURING J, VAN DER MEULEN Y et al. (2003). Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging. NMR Biomed, 16: 12-18.
46. SHIMIZU H, KUMABE T, TOMINAGA T et al. (1996). Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. AJNR Am J Neuroradiol, 17: 737-747.
47. SIJENS PE, KNOPP MV, BRUNETTI A et al. (1995). 1H MR spectroscopy in patients with metastatic brain tumors: a multicenter study. Magn Reson Med, 33: 818-826.
48. SUGAHARA T, KOROGI Y, SHIGEMATSU Y et al. (1999). Perfusion-sensitive MRI of cerebral lymphomas: a preliminary report. J Comput Assist Tomogr, 23: 232-237.
49. SUGAHARA T, KOROGI Y, TOMIGUCHI S et al. (2000). Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol, 21: 901-909.
50. TASCHNER CA, WETZEL SG, TOLNAY M, FROEHLICH J, MERLO A, RADUE EW. (2005). Characteristics of ultrasmall superparamagnetic iron oxides in patients with brain tumors. AJR Am J Roentgenol, 185: 1477-1486.
51. TZIKA AA, ASTRAKAS LG, ZARIFI MK et al. (2004). Spectroscopic and perfusion magnetic resonance imaging predictors of progression in pediatric brain tumors. Cancer, 100: 1246-1256.
52. WITWER BP, MOFTAKHAR R, HASAN KM et al. (2002). Diffusion-tensor imaging of white matter tracts in patients with cerebral neoplasm. J Neurosurg, 97: 568-575.
53. WONG JC, PROVENZALE JM, PETRELLA JR. (2000). Perfusion MR imaging of brain neoplasms. AJR Am J Roentgenol, 174: 1147-1157.
54. ZIEGLER A, VON KIENLIN M, DECORPS M, REMY C. (2001). High glycolytic activity in rat glioma demonstrated in vivo by correlation peak 1H magnetic resonance imaging. Cancer Res, 61: 5595-5600.